SERUM ADIPOKINES AND ADIPOKINE RECEPTORS IN COLON CANCER PATIENTS WITH METABOLOC SYNDROM
Abstract
Purpose: to study serum adipokine levels and AdipoR1, AdipoR2 and sOb-R expressions with respect to clinical-morphological parameters and the evidence of metaboloc syndrome (MS) in patients with stage I–III colon cancer.
Materials and methods. The study included 31 colon cancer patients having metabolic syndrome and patients having no metabolic syndrome. Serum levels of leptin, adiponektin, AdipoR1, AdipoR2 and soluble form of the leptin receptor was assessed by ELISA.
Results and conclusion. The incidence of MS in colon cancer patients was 71 %. The relationship between the serum leptin level and gender and disease stage was revealed. The tendency toward increase in the leptin level in patients with MS was shown. The Ob-R level was higher in patients having no MS. The levels of AdipoR1 and AdipoR2 were significantly higher in female colon cancer patients. Adiponectin receptors tended to increase in colon cancer patients with MS.
About the Authors
N. V. Yunusova
Tomsk Cancer Research Institute
Siberian State Medical University, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
I. V. Kondakova
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
S. G. Afanasyev
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
О. V. Shatokhina
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
N. P. Kovalyeva
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
А. Е. Frolova
Siberian State Medical University, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Е. S. Kolegova
Siberian State Medical University, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
References
1. Bochkareva N.V., Kolomiec L.A., Kondakova I.V., Muntjan A.B., Stukanov S.L., Fomina S.V. Prognostic significance of assay of sex hormones, their receptors and enzymes involved in estrogen synthesis and metabolism in endometrial carcinoma // Voprosy onkologii. 2007. Vol. 53 (3). P. 315–320. [in Russian]
2. Bochkareva N.V., Kolomiec L.A., Kondakova I.V., Stukanov S.L., Starova A.B., Agarkova L.A. Enzymes of estrogen metabolism in endometrial cancer // Bjulleten’ jeksperimental’noj biologii i mediciny. 2006. Vol. 141 (2). P. 202–204. [in Russian]
3. Bochkareva N.V., Kolomiec L.A., Kondakova I.V. Coexistence of endometrial hyperplasia and cancer with uterine myoma: the role of sex hormones, their receptors and enzymes of estrogen metabolism // Voprosy onkologii. 2005. Vol. 51 (4). P. 427–433. [in Russian]
4. Bochkareva N.V., Kondakova I.V., Kolomiec L.A., Chernyshova A.L. Insulin-like growth factors and insulin-like growth factor binding proteins in pathogenesis of endometrial cancer // Sibirskiy onkologicheskiy zhurnal. 2008. № 3. P. 86–93. [in Russian]
5. Chernyshova A.L., Kolomiec L.A., Bochkareva N.V., Asadchikova O.N. Metabolic syndrome, the relation with endometrial cancerogenesis // Sibirskiy onkologicheskiy zhurnal. 2008. № 5. P. 68–74. [in Russian]
6. Esposito K., Chiodini P., Colao A., Lenzi A., Giugliano D. Metabolic syndrome and risk of cancer. A systematic review and meta-analysis // Diabetes Care. 2012. Vol. 35. P. 2402–2411. doi: 10.2337/dc12-0336.
7. Jaffe T., Schwartz B. Leptin promotes motility and invasiveness in human cancer by activating multiple signal-transduction pathways // Int. J. Cancer. 2008. Vol. 123 (11). P. 2543–2556. doi: 10.1002/ijc.23821.
8. Liu H., Wan D., Pan Z., Cao L., Wu X., Lu Z., Kang T. Expression and biological significance of leptin, leptin receptor, VEGF, and CD 34 in colorectal carcinoma // Cell Biochem. Biophys. 2011. Vol. 60 (3). P. 241–244. doi: 10.1007/s12013-010-9145-5.
9. Ogunwobi O.O., Beales I.L. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3kinase/Akt // Int. J. Colorectal. Dis. 2007. Vol. 22 (4). P. 401–409.
10. Rosato V., Zucchetto A., Bosetti C., Bosetti C., Dal Maso L., Montella M., Pelucchi C., Negri E., Franceschi F., La Vecchia C. Metabolic syndrome and endometrial cancer risk // Ann. Oncol. 2011. Vol. 22 (4). P. 884–889. doi: 10.1093/annonc/mdq464.
11. Samani A.A., Yakar S., Leroith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insight // Endocr. Rev. 2007. Vol. 28 (1). P. 20–47.
12. Wang D., Chen J., Chen H., Duan Z., Xu Q., Wei M., Wang L., Zhong M. Leptin regulates proliferation and apoptosis of colorectal carcinomas through PIK/Akt/mTOR signaling pathway // J. Biosci. 2012. Vol. 37 (1). P. 91–101.
13. Williams C., Nicholas M., Sozopoulos E., His A., Wolk A., Nifli A-P., Tseleni-Balafouta S., Mantzoros C.S. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors // Endocr. Relat. Cancer. 2008. Vol. 15 (1). P. 289–299. doi: 10.1677/ERC-07-0197.
14. Yoneda K., Tomimoto A., Endo H., Iida H., Sugiyama M., Takahashi H. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue // Oncol. Rep. 2008. Vol. 20 (3). P. 479–483.
15. Zhou J.R., Blackburn G.L., Walker W.A. Symposium introduction: metabolic syndrome and the onset of cancer // Am. J. Clin. Nutr. 2007. Vol. 86 (3). S. 817–819.
Review
For citations:
Yunusova N.V., Kondakova I.V., Afanasyev S.G., Shatokhina О.V., Kovalyeva N.P., Frolova А.Е., Kolegova Е.S. SERUM ADIPOKINES AND ADIPOKINE RECEPTORS IN COLON CANCER PATIENTS WITH METABOLOC SYNDROM. Siberian journal of oncology. 2014;(5):24-28. (In Russ.)
Views:
543
Email this article 
